Intermittent Fugu parathyroid hormone 1 (1-34) is an anabolic bone agent in young male rats and osteopenic ovariectomized rats

Bone

Volumn 42, Issue 6, 2008, Pages 1164-1174

  McManus, Julie F ^a   Davey, Rachel A ^a   MacLean, Helen E ^a   Doust, Elizabeth A ^a   Chiu, W S Maria ^a   Sims, Natalie A ^b   Bouxsein, Mary L ^c   Glatt, Vaida ^c   Zajac, Jeffrey D ^a   Danks, Janine A ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Anabolic; Bone formation; Fish; Osteoporosis; Parathyroid hormone

Indexed keywords

ANABOLIC AGENT; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34];

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MASS; BONE STRENGTH; CELL COUNT; CONTROLLED STUDY; CORTICAL BONE; DRUG EFFECT; FEMALE; HORMONE ACTION; MALE; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; PUFFER FISH; RAT; TIBIA; TRABECULAR BONE; VERTEBRA;

ANABOLIC AGENTS; ANIMALS; BIOLOGICAL MARKERS; BONE AND BONES; BONE DISEASES, METABOLIC; FEMALE; HUMANS; MALE; OSTEOGENESIS; OSTEOPOROSIS; OVARIECTOMY; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; STRESS, MECHANICAL; TAKIFUGU;

EID: 43149105569     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2008.01.015     Document Type: Article

References (38)

1. Nguyen T., Sambrook P., Kelly P., Jones G., Lord S., Freund J., and Eisman J. Prediction of osteoporotic fractures by postural instability and bone density. BMJ 307 (1993) 1111-1115
2. Hutchinson T.A., Polansky S.M., and Feinstein A.R. Post-menopausal oestrogens protect against fractures of hip and distal radius. A case-control study. Lancet 2 (1979) 705-709
3. Bruyere O., Edwards J., and Reginster J.Y. Fracture prevention in postmenopausal women. Clin Evid (2003) 1304-1322
4. O'Neill S., MacLennan A., Bass S., Diamond T., Ebeling P., Findlay D., et al. Guidelines for the management of postmenopausal osteoporosis for GPs. Aust Fam Physician 33 (2004) 910-919
5. O'Donnell S., Cranney A., Wells G.A., Adachi J.D., and Reginster J.Y. Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev (2006) CD005326
6. Murray T.M., Rao L.G., Divieti P., and Bringhurst F.R. Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl-terminal ligands. Endocr Rev 26 (2005) 78-113
7. Samnegard E., Iwaniec U.T., Cullen D.M., Kimmel D.B., and Recker R.R. Maintenance of cortical bone in human parathyroid hormone(1-84)-treated ovariectomized rats. Bone 28 (2001) 251-260
8. Meng X.W., Liang X.G., Birchman R., Wu D.D., Dempster D.W., Lindsay R., et al. Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats. J Bone Miner Res 11 (1996) 421-429
9. Vahle J.L., Sato M., Long G.G., Young J.K., Francis P.C., Engelhardt J.A., et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 30 (2002) 312-321
10. Lane N.E., Kimmel D.B., Nilsson M.H., Cohen F.E., Newton S., Nissenson R.A., et al. Bone-selective analogs of human PTH(1-34) increase bone formation in an ovariectomized rat model. J Bone Miner Res 11 (1996) 614-625
11. Lane N.E., Yao W., Kinney J.H., Modin G., Balooch M., and Wronski T.J. Both hPTH(1-34) and bFGF increase trabecular bone mass in osteopenic rats but they have different effects on trabecular bone architecture. J Bone Miner Res 18 (2003) 2105-2115
12. Kasukawa Y., Miyakoshi N., Itoi E., Tsuchida T., Tamura Y., Kudo T., et al. Effects of h-PTH on cancellous bone mass, connectivity, and bone strength in ovariectomized rats with and without sciatic-neurectomy. J Orthop Res 22 (2004) 457-464
13. Kimmel D.B., Bozzato R.P., Kronis K.A., Coble T., Sindrey D., Kwong P., et al. The effect of recombinant human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats. Endocrinology 132 (1993) 1577-1584
14. Yao W., Hadi T., Jiang Y., Lotz J., Wronski T.J., Lane, and NE. Basic fibroblast growth factor improves trabecular bone connectivity and bone strength in the lumbar vertebral body of osteopenic rats. Osteoporos Int 16 (2005) 1939-1947
15. Zhang K.Q., Chen J.W., Li Q.N., Li G.F., Tian X.Y., Huang L.F., et al. Effect of intermittent injection of recombinant human parathyroid hormone on bone histomorphometry of ovariectomized rats. Acta Pharmacol Sin 23 (2002) 659-662
16. Zhou H., Iida-Klein A., Lu S.S., Ducayen-Knowles M., Levine L.R., Dempster D.W., and Lindsay R. Anabolic action of parathyroid hormone on cortical and cancellous bone differs between axial and appendicular skeletal sites in mice. Bone 32 (2003) 513-520
17. Alexander J.M., Bab I., Fish S., Muller R., Uchiyama T., Gronowicz G., et al. Human parathyroid hormone 1-34 reverses bone loss in ovariectomized mice. J Bone Miner Res 16 (2001) 1665-1673
18. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344 (2001) 1434-1441
19. Ebeling P.R., and Russell R.G. Teriparatide (rhPTH 1-34) for the treatment of osteoporosis. Int J Clin Pract 57 (2003) 710-718
20. Tashjian Jr. A.H., and Gagel R.F. Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res 21 (2006) 354-365
21. Vahle J.L., Long G.G., Sandusky G., Westmore M., Ma Y.L., and Sato M. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 32 (2004) 426-438
22. Danks J.A., Ho P.M., Notini A.J., Katsis F., Hoffmann P., Kemp B.E., et al. Identification of a parathyroid hormone in the fish Fugu rubripes. J Bone Miner Res 18 (2003) 1326-1331
23. Gardella T.J., and Juppner H. Interaction of PTH and PTHrP with their receptors. Rev Endocr Metab Disord 1 (2000) 317-329
24. Wade G.N. Gonadal hormones and behavioral regulation of body weight. Physiol. Behav. 8 (1972) 523-534
25. Davey R.A., and Morris H.A. The effects of salmon calcitonin-induced hypocalcemia on bone metabolism in ovariectomized rats. J Bone Miner Metab 23 (2005) 359-365
26. Sims N.A., Clement-Lacroix P., Da Ponte F., Bouali Y., Binart N., Moriggl R., et al. Bone homeostasis in growth hormone receptor-null mice is restored by IGF-I but independent of Stat5. J Clin Invest 106 (2000) 1095-1103
27. Meinel L., Fajardo R., Hofmann S., Langer R., Chen J., Snyder B., et al. Silk implants for the healing of critical size bone defects. Bone 37 (2005) 688-698
28. Hildebrand T., and Ruegsegger P. Quantification of bone microarchitecture with the structure model index. Comput Methods Biomech Biomed Engin 1 (1997) 15-23
29. Sato M., Vahle J., Schmidt A., Westmore M., Smith S., Rowley E., et al. Abnormal bone architecture and biomechanical properties with near-lifetime treatment of rats with PTH. Endocrinology 143 (2002) 3230-3242
30. Armamento-Villareal R., Sheikh S., Nawaz A., Napoli N., Mueller C., Halstead L.R., et al. A new selective estrogen receptor modulator, CHF 4227.01, preserves bone mass and microarchitecture in ovariectomized rats. J Bone Miner Res 20 (2005) 2178-2188
31. Turner C.H., and Burr D.B. Basic biomechanical measurements of bone: a tutorial. Bone 14 (1993) 595-608
32. Frolik C.A., Cain R.L., Sato M., Harvey A.K., Chandrasekhar S., Black E.C., et al. Comparison of recombinant human PTH(1-34) (LY333334) with a C-terminally substituted analog of human PTH-related protein(1-34) (RS-66271): in vitro activity and in vivo pharmacological effects in rats. J Bone Miner Res 14 (1999) 163-172
33. Orwoll E.S., Scheele W.H., Paul S., Adami S., Syversen U., Diez-Perez A., et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18 (2003) 9-17
34. Hodsman A.B., Kisiel M., Adachi J.D., Fraher L.J., and Watson P.H. Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis. Bone 27 (2000) 311-318
35. Dobnig H., Sipos A., Jiang Y., Fahrleitner-Pammer A., Ste-Marie L.G., Gallagher J.C., et al. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 90 (2005) 3970-3977
36. Pierroz D.D., Bouxsein M.L., Rizzoli R., and Ferrari S.L. Combined treatment with a beta-blocker and intermittent PTH improves bone mass and microarchitecture in ovariectomized mice. Bone 39 (2006) 260-267
37. Mosekilde L., Danielsen C.C., Sogaard C.H., McOsker J.E., and Wronski T.J. The anabolic effects of parathyroid hormone on cortical bone mass, dimensions and strength-assessed in a sexually mature, ovariectomized rat model. Bone 16 (1995) 223-230
38. Kneissel M., Boyde A., and Gasser J.A. Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH(1-34). Bone 28 (2001) 237-250